A detailed history of Hexagon Capital Partners LLC transactions in Astrazeneca PLC stock. As of the latest transaction made, Hexagon Capital Partners LLC holds 4,723 shares of AZN stock, worth $317,291. This represents 0.07% of its overall portfolio holdings.

Number of Shares
4,723
Previous 4,691 0.68%
Holding current value
$317,291
Previous $365,000 0.82%
% of portfolio
0.07%
Previous 0.08%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 08, 2024

BUY
$76.67 - $87.62 $2,453 - $2,803
32 Added 0.68%
4,723 $368,000
Q2 2024

Jul 12, 2024

BUY
$66.81 - $80.83 $96,674 - $116,961
1,447 Added 44.61%
4,691 $365,000
Q1 2024

Apr 18, 2024

BUY
$61.03 - $69.57 $17,881 - $20,384
293 Added 9.93%
3,244 $219,000
Q4 2023

Feb 05, 2024

BUY
$61.89 - $69.28 $70,307 - $78,702
1,136 Added 62.59%
2,951 $198,000
Q3 2023

Oct 23, 2023

SELL
$64.85 - $71.7 $18,676 - $20,649
-288 Reduced 13.69%
1,815 $122,000
Q2 2023

Jul 24, 2023

BUY
$69.91 - $75.81 $33,486 - $36,312
479 Added 29.5%
2,103 $150,000
Q1 2023

Apr 24, 2023

BUY
$63.15 - $71.6 $8,967 - $10,167
142 Added 9.58%
1,624 $112,000
Q4 2022

Jan 13, 2023

BUY
$54.21 - $70.44 $11,113 - $14,440
205 Added 16.05%
1,482 $0
Q3 2022

Oct 17, 2022

BUY
$53.02 - $135.75 $28,842 - $73,848
544 Added 74.22%
1,277 $70,000
Q2 2022

Jul 21, 2022

BUY
$59.26 - $71.14 $30,163 - $36,210
509 Added 227.23%
733 $48,000
Q4 2021

Jan 27, 2022

SELL
$54.02 - $63.83 $3,943 - $4,659
-73 Reduced 24.58%
224 $13,000
Q2 2021

Aug 11, 2021

SELL
$48.42 - $60.18 $1,743 - $2,166
-36 Reduced 10.81%
297 $18,000
Q1 2021

May 13, 2021

BUY
$47.16 - $54.44 $12,261 - $14,154
260 Added 356.16%
333 $16,000
Q4 2020

Feb 05, 2021

SELL
$48.52 - $58.02 $2,620 - $3,133
-54 Reduced 42.52%
73 $3,000
Q3 2020

Nov 10, 2020

BUY
$53.07 - $61.1 $6,739 - $7,759
127 New
127 $6,000

Others Institutions Holding AZN

About ASTRAZENECA PLC


  • Ticker AZN
  • Exchange OTC
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 3,099,020,032
  • Market Cap $208B
  • Description
  • AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, By...
More about AZN
Track This Portfolio

Track Hexagon Capital Partners LLC Portfolio

Follow Hexagon Capital Partners LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Hexagon Capital Partners LLC, based on Form 13F filings with the SEC.

News

Stay updated on Hexagon Capital Partners LLC with notifications on news.